In Vitro Effects on MCF-7 Breast Cancer Cells Of Signal Transduction Inhibitor/Tamoxifen/Eicosapentaenoic Acid Combinations and their Simultaneous Delivery Across Skin
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To determine the in vitro effects of simultaneously administered LY29400, PD98059, tamoxifen and eicosapentaenoic acid (EPA) on breast cancer cells, and determine their transcutaneous delivery.
Growth assays were performed on MCF-7 cells challenged with IC50 and permeated concentrations of PD98059, LY294002 and tamoxifen firstly in isolation then combined. Permeation studies were performed using PD98059 and LY294002 (singly or simultaneously) in DMSO then fish oil, with enhancers. Immunocytochemical detection of phospho-MAPK, phospho-Akt, total COX-2 and Ki-67 was performed.
When applied singly, fluxes of PD98059 and LY294002 were 0.09 ± 0.008 and 0.14 ± 0.045 μg cm−2 h−1, respectively; applied simultaneously, 0.18 ± 0.045 and 0.49 ± 0.051 μg cm−2 h−1. Permeated concentrations of PD98059 and LY294002 reduced growth to 13.78 ± 0.63%. Fish oil plus 2.5% DMSO/ethanol allowed 5.96 ± 0.9 and 7.7 ± 1.2 μg cm−2 of PD98059 and LY294002 to permeate after 48 h.
PD98059 and LY294002 permeate excised skin at therapeutically useful rates, and also demonstrate growth inhibitory effects on MCF-7 cancer cells. Synergism was noted in co-transport across skin and activity against cancer cells. A formulation based on fish oil is potentially skin friendly; simultaneous permeation of EPA provides further anti-cancer action.
- S. Ali, and R. C. Coombes. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer. 2:101–112 (2002). CrossRef
- R. B. Riggins, K. S. Thomas, H. Q. Ta, J. Wen, R. J. Davis, N. R. Schuh, S. S. Donelan, K. A. Owen, M. A. Gibson, M. A. Shupnik, C. M. Silva, S. J. Parsons, R. Clarke, and A. A. Bouton. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res. 66:7007–7015 (2006). CrossRef
- L. A. deGraffenried, L. Fulcher, W. E. Friedrichs, V. Grünwald, R. B. Ray, and M. Hidalgo. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 15:1510–1516 (2004). CrossRef
- J. M. Knowlden, I. R. Hutcheson, H. E. Jones, T. Madden, J. M. W. Gee, M. E. Harper, D. Barrow, A. E. Wakeling, and R. I. Nicholson. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044 (2003). CrossRef
- R. I. Nicholson, C. Staka, F. Boynes, I. R. Hutheson, and J. M. W. Gee. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr.-Relat. Cancer. 11:1–9 (2004). CrossRef
- R. A. Campbell, P. Bhat-Nakshatri, N. M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri. Phosphatidylinositol 3-kinase/Akt-mediated activation of estrogen receptor a, a new model for anti-estrogen resistance. J. Biol. Chem. 276:9817–9824 (2001). CrossRef
- N. J. Jordan, J. M. W. Gee, D. Barrow, A. E. Wakeling, and R. I. Nicholson. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res. Treat. 87:167–180 (2004). CrossRef
- A. Adeyinka, Y. Nui, T. Cherlet, L. Snell, P. H. Watson, and L. C. Murphy. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res. 8:1747–1753 (2002).
- M. Sun, J. E. Paciga, R. I. Feldman, Z.-Q. Yuan, D. Coppola, Y. Y. Lu, S. A. Shelley, S. V. Nicosia, and J. Q. Cheng. Phosphatidylinositol-3-OH kinase (P13K)/AKT2, activated in breast cancer, regulates and is induced by Estrogen Receptor (ER) via interaction between ER and PI3K. Cancer Res. 61:5985–5991 (2001).
- C. J. Vlahos, W. F. Matter, K. Y. Hui, and R. F. Brown. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269:5241–5248 (1994).
- K.-C. Choi, N. Auersperg, and P. C. K. Leung. Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reprod. Biol. Endocrinol. 1:71–78 (2003). CrossRef
- D. R. Alessi, A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. PD 098059 Is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489–27494 (1995). CrossRef
- S. Ho, R. J. Calder, C. M. Heard, and C. P. Thomas. In vitro transcutaneous delivery of tamoxifen and γ linolenic acid from a borage oil formulation containing ethanol and 1,8-cineole. J. Pharm. Pharmacol. 56:1–8 (2004).
- A. C. Williams. Topical and Transdermal Drug Delivery, Pharmaceutical, London, 2004.
- G. Davies, L.-A. Martin, N. Sacks, and M. Dowsett. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann. Oncol. 13:669–678 (2002). CrossRef
- M. L. Parrett, R. E. Harris, and F. S. Joarder. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 11:503–507 (1997).
- P. J. Wild, L. A. Kunz-Schughart, F. Bataille, R. Simon, G. Sauter, M. Mihatsch, and A. Hartmann. Strong COX-2 overexpression in breast and prostate cancer—a potential therapeutic target. Proc. Am. Assoc. Cancer Res. 45:3059 (2004).
- T. L. Larkins, M. Nowell, T. Wallace, and G. L. Sanford. Inhibition of COX-2 attenuates the motility and invasion of breast cancer cells. Proc. Am. Assoc. Cancer Res. 46:3059 (2005).
- E. W. Thompson, and M. Waltham. Stromal MMP targets for human breast cancer growth and progression. Tumor biology. Proc. Am. Assoc. Cancer Res. 47:937–939 (2006).
- C. P. Thomas, Z. Davison, and C. M. Heard. Probing the skin permeation of fish oil/EPA and ketoprofen 3. Influence of fish oil/ketoprofen on epidermal COX-2 and LOX. Prostaglandins Leukot. Essent. Fat. Acids. 76:357–362 (2007). CrossRef
- Y. I. Yarden, M. A. Wilson, and S. A. Chrysogelos. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell Biochem. 36:232–246 (2001). CrossRef
- S. Zhang, X. Li, R. Burghardt, R. Smith, and S. H. Safe. Role of estrogen receptor (ER)α in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells. J. Molec. Endocrinol. 35:433–447 (2005). CrossRef
- C. M. Heard, D. Kung, and C. P. Thomas. Skin penetration enhancement of mefenamic acid by ethanol and 1,8-cineole can be explained by the pull effect. Int. J. Pharm. 321:167–170 (2006). CrossRef
- C. M. Staka, R. I. Nicholson, and J. M. W. Gee. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr.-Relat. Cancer. 12:S85–S97 (2005). CrossRef
- C. M. Heard, J. L. Harwood, P. Maguire, G. McNaughton, and W. J. Pugh. Simultaneous penetration of NSAID and essential fatty acid esters as a dual-action anti-arthritis therapy. In K. R. Brain, and K. Walters (eds.), Perspectives in Percutaneous Penetration, Vol 8a, STS, Cardiff, 2002, p. 93.
- C. M. Heard, C. Congiatu, S. J. Gallagher, J. L. Harwood, C. Karia, C. McGuigan, M. Nemcova, T. Nouskova, and C. P. Thomas. Preferential π complexation between tamoxifen and borage oil/γ linolenic acid: transcutaneous delivery and NMR spectral modulation. Int. J. Pharm. 302:47–55 (2005). CrossRef
- C. Lassarre, and J.-M. Ricort. Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: Effects on the insulin-like growth factor signalling pathway. Endocrinology. 144:4811–4819 (2003). CrossRef
- In Vitro Effects on MCF-7 Breast Cancer Cells Of Signal Transduction Inhibitor/Tamoxifen/Eicosapentaenoic Acid Combinations and their Simultaneous Delivery Across Skin
Volume 25, Issue 11 , pp 2516-2525
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- breast cancer
- signal transduction inhibitor
- transcutaneous delivery
- Industry Sectors